Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 214-604-9
CAS number: 1163-19-5
14 d, 13 wk, 2 year studies in rats and mice.
The results of Norris et al. (1973, 1974,
1975) demonstrate that the former lower purity form of DecaBDE is
capable of causing changes in liver weight and hepatocytomegaly,
probably due to enzyme induction, as supported by the subtle changes in
CYP documented by Van der Ven et al. (2008). Though Van der Ven et al.
(2008) concluded that the commercial form of BDE-209 caused an effect on
the weights of the epididymis and seminal vesicle, Hardy et al. (2008)
showed that there were no statistically significant differences for
these endpoints, nor was there a visible dose response from these data
(Hardy et al., 2008). When considered in toto with the absence of any
histopathological changes in these tissues or with sperm parameters, Van
der Ven et al.’s (2008) conclusions are not supported by their data.
Finally, the NTP (1986) study demonstrated that dietary exposures did
not cause any gross or microscopic pathological effects in rats or mice
at doses up to 5% in the diet for 90 d. In their 2 year study at doses
up to 5% of the diet, nonneoplastic effects reported in male rats were
confined to the liver, spleen, and mandibular lymph nodes (NTP 1986). In
female rats, the only nonneoplastic effect to increase with dose was an
increase in nephropathy; however, this lesion was present in 84% of
control animals and is a common age-related lesion occurring in this
strain of rat. Degeneration of the eye was observed in low-dose female
rats (30%; cf. controls and high-dose groups = 10%). The NTP (1986) did
not consider this effect to be treatment related, because this effect
has been correlated with exposure to artificial light due to cage
placement, and as a result, US NTP’s long-term studies presently
incorporate cage rotation into the study design. This 2-year study was
conducted prior to US NTP instituting cage rotation as a part of their
experimental protocols. In male mice, nonneoplastic lesions were
observed in the liver, mandibular lymph node, and thyroid.
Non-neoplastic lesions in female mice were limited to the mandibular
lymph node. Notably, no test-article-related effect on mortality or body
weight was detected in the NTP 2 year studies in both species. NTP
estimated the doses in the 2 year study were: 1120 or 2240 mg/kg bw/d
(male rats), 1200 or 2550 mg/kg bw/d (female rats), 3200 or 6650 mg/kg
bw/d (male mice), and 3760 or 7780 mg/kg bw/d (female mice) at the low
and high doses, respectively. These results indicate a NOAEL in repeated
dose stuides of at least 1000 mg/kg bw/d for the commercial DecaBDE product.
DecaBDE has a NOAEL of at least 1000 mg/kg
bw/d in repeatd doses studies. Classification is not required.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Sellel veebilehel kasutatakse küpsiseid, et tagada lehe parim kasutus.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again